Cargando…

Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes

AIMS/INTRODUCTION: Recently, patient‐tailored statin therapy was proven effective for achieving target low‐density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type ...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Jang Won, Kim, Dong Jun, Lee, Chang Beom, Oh, Seungjoon, Song, Kee‐Ho, Jung, Chan Hee, Mok, Ji Oh, Kim, Jong Hwa, Moon, Min Kyong, Choi, Kyung Mook, Cho, Jae Hyoung, Choi, Sung Hee, Kim, Soo Kyung, Park, Kang Seo, Kim, Hye Soon, Kim, In Joo, Kim, Young Il, Kim, Hae Jin, Kim, Sang Yong, Kim, Sungrae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025110/
https://www.ncbi.nlm.nih.gov/pubmed/24843697
http://dx.doi.org/10.1111/jdi.12074
_version_ 1782316727210606592
author Son, Jang Won
Kim, Dong Jun
Lee, Chang Beom
Oh, Seungjoon
Song, Kee‐Ho
Jung, Chan Hee
Mok, Ji Oh
Kim, Jong Hwa
Moon, Min Kyong
Choi, Kyung Mook
Cho, Jae Hyoung
Choi, Sung Hee
Kim, Soo Kyung
Park, Kang Seo
Kim, Hye Soon
Kim, In Joo
Kim, Young Il
Kim, Hae Jin
Kim, Sang Yong
Kim, Sungrae
author_facet Son, Jang Won
Kim, Dong Jun
Lee, Chang Beom
Oh, Seungjoon
Song, Kee‐Ho
Jung, Chan Hee
Mok, Ji Oh
Kim, Jong Hwa
Moon, Min Kyong
Choi, Kyung Mook
Cho, Jae Hyoung
Choi, Sung Hee
Kim, Soo Kyung
Park, Kang Seo
Kim, Hye Soon
Kim, In Joo
Kim, Young Il
Kim, Hae Jin
Kim, Sang Yong
Kim, Sungrae
author_sort Son, Jang Won
collection PubMed
description AIMS/INTRODUCTION: Recently, patient‐tailored statin therapy was proven effective for achieving target low‐density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type 2 diabetes. MATERIALS AND METHODS: The present study was an 8‐week, multicenter, single‐step titration trial of patient‐tailored atorvastatin therapy (10, 20 and 40 mg) according to baseline LDL cholesterol levels in 440 patients with type 2 diabetes. We measured the LDL particle size by polyacrylamide gel electrophoresis, and used high‐sensitivity C‐reactive protein (hsCRP) and adiponectin as surrogate markers of inflammation. RESULTS: In the intention‐to‐treat analysis, 91% of the patients achieved their LDL cholesterol targets (<2.6 mmol/L) at week 8. There were significant reductions at week 8 in total cholesterol, triglycerides, non‐high‐density lipoprotein cholesterol (HDL) cholesterol, and the total cholesterol:HDL cholesterol ratio compared with the baseline values for all of the doses. The mean LDL particle size was significantly increased, and the small, dense LDL cholesterol levels were decreased in a dose‐dependent manner over the study period. In addition, the hsCRP levels were decreased in those high‐risk patients with baseline hsCRP levels over 3 mg/L (P < 0.001), and the adiponectin levels tended to increase with all of the doses (P = 0.004) at 8 weeks. CONCLUSIONS: Patient‐tailored atorvastatin therapy based on LDL cholesterol at baseline was effective in ameliorating atherogenic LDL particle size and inflammation, in addition to achieving the target LDL cholesterol level without an undesirable effect on glycemic control in patients with type 2 diabetes. This trial was registered with ClinicalTrials.gov (no. NCT01239849).
format Online
Article
Text
id pubmed-4025110
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Wiley-Blackwell
record_format MEDLINE/PubMed
spelling pubmed-40251102014-05-19 Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes Son, Jang Won Kim, Dong Jun Lee, Chang Beom Oh, Seungjoon Song, Kee‐Ho Jung, Chan Hee Mok, Ji Oh Kim, Jong Hwa Moon, Min Kyong Choi, Kyung Mook Cho, Jae Hyoung Choi, Sung Hee Kim, Soo Kyung Park, Kang Seo Kim, Hye Soon Kim, In Joo Kim, Young Il Kim, Hae Jin Kim, Sang Yong Kim, Sungrae J Diabetes Investig Articles AIMS/INTRODUCTION: Recently, patient‐tailored statin therapy was proven effective for achieving target low‐density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type 2 diabetes. MATERIALS AND METHODS: The present study was an 8‐week, multicenter, single‐step titration trial of patient‐tailored atorvastatin therapy (10, 20 and 40 mg) according to baseline LDL cholesterol levels in 440 patients with type 2 diabetes. We measured the LDL particle size by polyacrylamide gel electrophoresis, and used high‐sensitivity C‐reactive protein (hsCRP) and adiponectin as surrogate markers of inflammation. RESULTS: In the intention‐to‐treat analysis, 91% of the patients achieved their LDL cholesterol targets (<2.6 mmol/L) at week 8. There were significant reductions at week 8 in total cholesterol, triglycerides, non‐high‐density lipoprotein cholesterol (HDL) cholesterol, and the total cholesterol:HDL cholesterol ratio compared with the baseline values for all of the doses. The mean LDL particle size was significantly increased, and the small, dense LDL cholesterol levels were decreased in a dose‐dependent manner over the study period. In addition, the hsCRP levels were decreased in those high‐risk patients with baseline hsCRP levels over 3 mg/L (P < 0.001), and the adiponectin levels tended to increase with all of the doses (P = 0.004) at 8 weeks. CONCLUSIONS: Patient‐tailored atorvastatin therapy based on LDL cholesterol at baseline was effective in ameliorating atherogenic LDL particle size and inflammation, in addition to achieving the target LDL cholesterol level without an undesirable effect on glycemic control in patients with type 2 diabetes. This trial was registered with ClinicalTrials.gov (no. NCT01239849). Wiley-Blackwell 2013-09-13 2013-03-26 /pmc/articles/PMC4025110/ /pubmed/24843697 http://dx.doi.org/10.1111/jdi.12074 Text en Copyright © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd
spellingShingle Articles
Son, Jang Won
Kim, Dong Jun
Lee, Chang Beom
Oh, Seungjoon
Song, Kee‐Ho
Jung, Chan Hee
Mok, Ji Oh
Kim, Jong Hwa
Moon, Min Kyong
Choi, Kyung Mook
Cho, Jae Hyoung
Choi, Sung Hee
Kim, Soo Kyung
Park, Kang Seo
Kim, Hye Soon
Kim, In Joo
Kim, Young Il
Kim, Hae Jin
Kim, Sang Yong
Kim, Sungrae
Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
title Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
title_full Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
title_fullStr Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
title_full_unstemmed Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
title_short Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
title_sort effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025110/
https://www.ncbi.nlm.nih.gov/pubmed/24843697
http://dx.doi.org/10.1111/jdi.12074
work_keys_str_mv AT sonjangwon effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimdongjun effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT leechangbeom effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT ohseungjoon effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT songkeeho effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT jungchanhee effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT mokjioh effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimjonghwa effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT moonminkyong effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT choikyungmook effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT chojaehyoung effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT choisunghee effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimsookyung effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT parkkangseo effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimhyesoon effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kiminjoo effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimyoungil effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimhaejin effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimsangyong effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes
AT kimsungrae effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes